ADMA Biologics (ADMA) Stock Price Up 10.5%

ADMA Biologics Inc (NASDAQ:ADMA) rose 10.5% during trading on Friday . The company traded as high as $4.41 and last traded at $4.22. Approximately 1,011,871 shares were traded during mid-day trading, an increase of 75% from the average daily volume of 578,283 shares. The stock had previously closed at $3.82.

ADMA has been the topic of a number of analyst reports. HC Wainwright initiated coverage on ADMA Biologics in a research report on Tuesday, October 30th. They issued a “buy” rating and a $17.00 price target on the stock. Oppenheimer set a $13.00 target price on ADMA Biologics and gave the company a “buy” rating in a research report on Monday, November 12th. Finally, Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy adma” rating in a research report on Thursday, December 20th. Seven research analysts have rated the stock with a buy rating, ADMA Biologics has an average rating of “Buy” and an average price target of $10.42.

The company has a quick ratio of 4.92, a current ratio of 6.32 and a debt-to-equity ratio of 1.11. The stock has a market cap of $166.86 million, a P/E ratio of -2.21 and a beta of 2.88.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of ADMA Biologics by 0.5% during the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock valued at $2,305,000 after purchasing an additional 4,577 shares in the last quarter. Rhumbline Advisers boosted its position in shares of ADMA Biologics by 50.5% during the 4th quarter. Rhumbline Advisers now owns 23,279 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 7,810 shares in the last quarter. Raymond James & Associates boosted its position in shares of ADMA Biologics by 65.2% during the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares in the last quarter. United Services Automobile Association bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $27,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $34,000. Institutional investors own 57.72% of the company’s stock.

WARNING: “ADMA Biologics (ADMA) Stock Price Up 10.5%” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2019/02/15/adma-biologics-adma-stock-price-up-10-5.html.

ADMA Biologics Company Profile (NASDAQ:ADMA)

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: SEC Filing

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply